AcclaimIP-ad

Match Document Document Title
5164484 De-(acetylglucosaminyl-di(dehydro)-deoxy teicoplanin derivatives  
The present invention is directed to new de-(acetylglucosaminyl)-di(dehydro)deoxy teicoplanin derivatives which possess antibiotic activity mainly against gram positive bacteria.The new compounds...
5162111 Treatment of bacterial diseases with granulocyte-macrophage colony stimulating factor  
Subjects suffering from infectious diseases are treated by direct administration of therapeutically-effective quantities of granulocyte-macrophage colony stimulating factor employed by itself or...
5157106 N-terminal deletions of lymphotoxin, their preparation and use  
Polypeptides which differ from lymphotoxin by the absence of amino acids at the N-terminal end of the lymphotoxin are described. The polypeptides can be prepared by gene manipulation and are...
5157112 Antibodies immunoreactive with the T-cell growth factor, P40  
The present invention relates generally to a T cell growth factor. More particularly, the present invention relates to a T cell growth factor which comprises a glycoprotein which supports...
5157110 Synthetic, anti-complement protein  
A substantially pure, synthetic protein possessing anti-complement property and a DNA sequence encoding said protein are described.
5153176 Tripeptide derivatives and protease inhibitor composition comprising the same  
Tripeptide derivatives of formula (I) such as N-ε-(p-tosyl)-D-lysyl-L-prolyl-L-argininal have an activity of inhibiting a plurality of trypsin-like serine proteases, e.g., plasmin, thrombin,...
5149785 Proteins which regulate gene expression of the interleukin-2 receptor and of human lymphotropic retroviruses  
The present invention is directed to genes, termed Rpt-1 (regulatory protein T lymphocyte-1), which are expressed at higher levels by resting CD4+ helper/inducer T cells relative to activated CD4+...
5140103 Peptide fragments containing HP and LP cross-links  
A method of determining collagen degradation in vivo, including quantitating the concentration of a peptide in a body fluid, the peptide being a C-terminal type II collagen telopeptide containing...
5138036 Isolation and structural elucidation of the cytostatic cyclodepsipeptide dolastatin 14  
A new cytostatic depsipeptide, designated "dolastatin 14", was isolated from the Indian Ocean shell-less mollusk Dolabella auricularia. Dolastatin 14 inhibited growth of the PS leukemia with ED50...
5135912 Natriuretic peptides from the pituitary prohormone proopiomelanocortin  
Novel peptides having substantially the amino acid sequence: X-Gly-Asn-Gly-Asp-Glu-Gln-Pro-Leu-Thr-Y,where X is H, a single amino acid or a short-chain peptide and Y is OH, NH2, a single aminoacid...
5133961 Vaccines comprising yeast-derived hepatits B virus polypeptides  
The entire hepatitis B virus pre-S antigen gene linked in one contiguous reading frame to the hepatitus B virus surface antigen gene has been expressed in Saccharomyces cerevisiae. The expressed...
5134121 Nerve growth factor peptides  
The present invention provides both agonist and antagonist nerve growth factor peptides. The NGF blocking peptides can be used to inhibit the expression of mRNA and their encoded proteins whose...
5132111 CRF analog conjugates  
Agonists and antagonists of rCRF are disclosed that exhibit good binding affinity to CRF receptors. One exemplary agonist is: H-Ser-Gln-Glu-Pro-Pro-Ile-Ser-...
5130414 Isolation and structural elucidation of the cyclic peptide hymenistatin 1  
A new and demonstratably active cyclo-octapeptide is isolated from the South Pacific Ocean Hymeniacidon sp. and structurally elucidated. The substance, herein denominated Hymenistatin 1,...
5130417 Entamoeba histolytical immunogenic protein and cDNA clone  
An Entamoeba histolytica specific cDNA clone which encodes an antigenic surface membrane protein possessing multiple tandem repeats and expression in E. coli is disclosed.
5128447 Synthetic peptide antagonists of neurokinin A, salts thereof and respective preparation processes  
A synthetic peptide corresponding to the following formula: X--Asp--Y--DTrp--Val--DTrp--Z--K--NH2where: X=H, Arg, DArg, Lys, DLys, Thr, DThr Y=Tyr, Trp, DTrp, Ser, Met Z=Trp, DTrp K=Arg, Phe,...
5128450 Nonglycosylated human interleukin-3 analog proteins  
The present invention provides a pharmaceutical compositions comprising as active ingredients certain truncated purified human IL-3(Pro8 Asp15 Asp70) analog proteins expressed by transformed yeast...
5128242 Hypothalamic polypeptides with adenylate cyclase stimulating activity  
The present invention relates to peptides having adenylate cyclase stimulating activity. The peptides all have at least the sequence His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-...
5126322 Pancreatic secretory tryspin inhibitor and variants thereof produced by a recombinant host therefore and pharmaceutical use thereof  
The present invention relates to a peptide having essentially the amino acid sequence of pancreatic secretory trypsin inhibitor (PSTI). The present invention also relates to variants of such...
5122448 Assay of anti-Epstein-Barr virus nuclear antigen antibodies with synthetic polypeptides  
Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems...
5122376 Calcitonin gene related peptide  
Compositions comprising a calcitonin gene related peptide and, as an absorption enhancer, a glycyrrhizinate.
5116942 Protein having an inflammatory phospholipase A2 inhibitory activity  
Protein having inflammatory phospholipase A2 inhibitory activity wherein said protein has a nature to be induced from cells by administration of glucocorticoid, for example, having a molecular...
5116947 Process for the preparation of retro-inverso peptides and new intermediates thereof  
A method of synthesis of a partially retro-inverso peptide incorporating at least one malonyl residue of formula (III) ##STR1## wherein R represents the side chain of an α-amino acid, is described...
5116725 Assay for Epstein-Barr virus infection with solid phase bound synthetic polypeptides  
Antigens, immunogens, inocula, antibodies, and particularly diagnostic methods and systems relating to Epstein-Barr virus nuclear antigen (EBNA) are disclosed. The diagnostic methods and systems...
5116818 Method and kit for contraception with GnRH-antagonist  
A method of providing contraception for and regulation of the menstrual cycle of a gonadal female mammal by a) administering thereto about once a week throughout her menstrual cycle an amount of a...
5116815 PF 1022 substance, method of treating helminthic parasitic infection and anthelmintic composition  
A novel substance having anthelmintic activity, the PF 1022 substance, which is produced by cultivating a fungal strain capable of producing the substance and recovering the substance from the...
5114843 Humoral hypercalcemic factor antagonists  
The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide analogues is exemplified by an internal...
5114845 Assays for plasminogen activator inhibitor and soluble fibrin  
The present invention relates to an improved method for measuring soluble fibrin utilizing a genetically modified tissue plasminogen activator protein as a substrate.
5114918 Endothelin antagonistic cyclic pentapeptides  
Cyclic pentapeptides of the formula: cyclo (-X1 -X2 -X3 -X4 -X5 -) (I)wherein Xn (n=1-5) represents amino acid residues. These compounds are useful as hypotensive drugs.
5114711 Covalently linked polypeptide cell modulators such as interferon-lymphotoxin conjugates  
Described is a new class of polypeptide cell modulators characterized by being composed of two covalently linked cell modulators in a linear polypeptide sequence. Such dual function polypeptides...
5112944 Cyclic tetrapeptide and process for preparing the same  
A cyclic tetrapeptide having the formula (I): ##STR1## wherein n is 4 or 3 and a process for preparing the above cyclic tetrapeptide. The cyclic tetrapeptide of the present invention inhibits...
5112808 Alkylated hormone-releasing peptides and method of treatig mammals therewith  
This invention provides novel growth hormone-releasing peptides and a method for increasing the release and raising the levels of growth hormone in mammals. The invention also provides a method...
5112806 Antibiotic, mersacidin, a process for the preparation thereof and the use thereof as a pharmaceutical  
Mersacidin, a cyclic peptide of the formula I ##STR1## has antibiotic activity.
5109111 CRF antagonists  
Several known members of the corticotropin releasing factor (CRF) family have been synthesized and tested, including human and rat CRF which have the formula:...
5104977 Purified transforming growth factor beta  
A composition for the promotion of cell proliferation and tissue repair in animals having as active ingredients a TGF-β which is activated by either a TGF-α or an EGF or both; and methods for...
5102872 Controlled-release formulations of interleukin-2  
Shipping fever, and other stress-related diseases in livestock, are treated by administration of a microencapsulated composition comprising IL-2 conjugated with a polyoxyethylene polymer, and...
5093233 Antagonists with position 13 modification  
The present invention relates to the use of peptide hormone analogues as inhibitors of their respective naturally occurring peptide hormone. The structure of the peptide hormone analogues is...
5091366 Peptides having ANF activity  
Analogs of the 17-membered ring portion of ANF wherein the cysteine moiety is replaced with dipeptidyl moieties, specifically, Phe-Pro, NMP-Pro, Pro-Pro, Val-Pro, Lys-Pro, Ile-Pro, Arg-Pro,...
5087561 Humoral hypercalcemic factor antagonists modified at position 13 by biotin  
The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human...
5087562 Humoral hypercalcemic factor antagonists with modification at position 13 . . .  
The present invention relates to the use of peptide analogues as inhibitors of their respective naturally occurring peptides. The structure of the peptide hormone analogues is exemplified by human...
5081028 Preparation of transformed hosts which express binding factor related polypeptides  
The invention concerns polypeptides related to human immunoglobulin E binding factors (IgE-Bfs), mRNa, DNAs and hybrid vectors coding for said polypeptides, hosts containing said hydrid vectors,...
5071761 Hybrid interferons  
Novel hybrid interferons are produced which are derived from lymphoblastoid interferons α-2 and α-3 belonging to the interferon αB and αD groups, respectively. The novel hybrid interferons possess...
5051496 Peptides related to human immunodeficiency virus II (HIV-2)  
A method for diagnosing an HIV-2 (LAV-II) infection and a kit containing reagents for the same is disclosed. These reagents include cDNA probes which are capable of hybridizing to at least a...
5030449 Synthetic vaccine against AIDS virus  
The invention relates to peptide antigens which stimulate helper T lympocytes which specifically recognize HIV envelope protein, thereby enhancing antibody production and cytotoxic T cells to...
5028425 Synthetic vaccine against P. falciparum malaria  
A purified peptide which induces proliferation or activation of cytotoxic T cells specifically against circumsporozoite protein of P. falciparum is described. The peptide has an amino acid...
5019386 Hepatitis B vaccine  
A polypetide vaccine is disclosed with the amino acid sequence of Asp-Pro-Arg-Val-Arg-Gly-Leu-Try-Phe-Pro-Ala-Gly-Gly-Ser-Ser- Ser-Gly-Thr-Va l that bears the receptor for polymerized human serum...
5019387 Production of antibodies to HIV  
The present invention relates to immunogenic preparations of peptides comprising amino acid sequences corresponding to antigenic determinants of the envelope glycoprotein of HIV, covalently...
4997647 Vaccine against the sporozoite stage of malaria  
Described is an immunogenic polypeptide that is a portion of the P. vivax circumsporozoite expressed by a recombinant yeast.
4983387 HIV related peptides, immunogenic antigens, and use therefor as subunit vaccine for AIDS virus  
Vaccines effective in the inhibition of infection caused by the family of retroviruses, HTLV-III, Human T-Cell Leukemia Virus, LAV, Lymphadenopathy-associated virus, ARV-2, AIDS-Related Virus,...
4957737 HTLV-III (LAV) envelope peptides  
Synthetic peptides containing the epitopic sequence HTLV env (578-608) are useful as reagents in immunoassays for detection of AIDS antibodies, as immunogens for eliciting polyclonal or monoclonal...